"10.1371_journal.pone.0023570","plos one","2011-08-26T00:00:00Z","Weike Bao; Karpagam Aravindhan; Hasan Alsaid; Thimmaiah Chendrimada; Matthew Szapacs; David R Citerone; Mark R Harpel; Robert N Willette; John J Lepore; Beat M Jucker","Heart Failure Discovery Performance Unit, Metabolic Pathways and Cardiovascular Therapy Area Unit, GlaxoSmithKline, King of Prussia, Pennsylvania, United States of America; Clinical Imaging Center, GlaxoSmithKline, King of Prussia, Pennsylvania, United States of America; Platform Technology and Science, GlaxoSmithKline, King of Prussia, Pennsylvania, United States of America","Conceived and designed the experiments: WB BMJ. Performed the experiments: WB KA HA TC MS DRC BMJ. Analyzed the data: WB KA HA TC MS DRC MRH BMJ. Wrote the paper: WB RNW JJL BMJ.","All authors are employees of GlaxoSmithKline. This does not alter the authorsâ€˜ adherence to all the PLoS ONE policies on sharing data and materials. In addition, Albiglutide is in clinical development, but not a marketed product.","2011","08","Weike Bao","WB",10,TRUE,2,7,8,4,TRUE,TRUE,FALSE,0,NA,FALSE
